Berberine (BBR), a common anti-inflammatory drug, has been found to specifically bind to the Glu76 site of CSN5, thereby inhibiting the deubiquitination activity of CSN5 in non-small cell lung cancer, reducing the expression of PD-L1, and promoting antitumor immunity[66]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.